<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01779908</url>
  </required_header>
  <id_info>
    <org_study_id>CDA grant no OG-3-12-3681-CG</org_study_id>
    <secondary_id>B12-12-1095</secondary_id>
    <nct_id>NCT01779908</nct_id>
  </id_info>
  <brief_title>Role of Vitamin D in the Prevention and Treatment of Diseases Associated With Insulin Resistance</brief_title>
  <acronym>VIDIR</acronym>
  <official_title>Role of Vitamin D in the Prevention and Treatment of Diseases Associated With Insulin Resistance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CHU de Quebec-Universite Laval</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Canadian Diabetes Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Laval University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fonds de la Recherche en Santé du Québec</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>CHU de Quebec-Universite Laval</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, randomized and placebo-controlled 6-month trial of vitamin D supplementation in
      130 Caucasian and vitamin D-deficient men and women aged 25 years and over. Participants will
      have abdominal obesity and at least one factor associated with insulin resistance.
      Participants will be randomized by sex, BMI and age. The primary aim is to compare the effect
      of daily vitamin D3 (cholecalciferol, 5000 IU) vs. placebo for 6 mo on insulin sensitivity
      (M-value by the gold standard method, the euglycemic hyperinsulinemic clamp). Secondary aims
      are to evaluate the effects of vitamin D3 vs. placebo on other indices of glucose metabolism,
      the lipid profile, blood pressure and anthropometric measurements. Questionnaires on physical
      activity and sunlight exposure, and a food frequency questionnaire will be administered at 0
      and 6 mo to adjust for confounding factors. At 0 and 6 mo, changes in serum 25(OH)D will be
      correlated with changes in blood markers associated with insulin sensitivity [hs-CRP,
      inflammatory cytokines (IL-6 and TNF-alpha), adiponectin, leptin, total and undercarboxylated
      osteocalcin].

      This research project intends to test 2 major hypotheses: (1) that vitamin D deficiency plays
      a causal role in the pathogenesis of insulin resistance in humans; and (2) that vitamin D
      increases insulin sensitivity.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Part 1: Prospective, randomized and placebo-controlled 6-month trial of vitamin D
      supplementation in 130 Caucasian and vitamin D-deficient [serum 25(OH)D ≤55 nM] men and women
      aged 25 years and over with a BMI ≤40 kg/m2. Participants will have abdominal obesity
      (increased waist circumference of at least 102 cm for men and 88 cm for women) and at least
      one factor associated with insulin resistance, namely: (1) serum triglyceride levels of at
      least 1.7 mmol/L or treated dyslipidemia; (2) prediabetes or untreated type 2 diabetes (HbA1c
      &gt;=5.6% or fasting glucose &gt;=5.6 mmol/L or glucose 2h post OGTT &gt;=7.8 mmol/L); (3) first
      degree relative with type 2 diabetes; (4) history of gestational diabetes. Participants will
      be randomized according to sex, BMI (&lt;30 kg/m2 vs. 30 kg/m2 and over) and age (&lt; or &gt;=50
      years old). The primary aim is to compare the effect of daily vitamin D3 (cholecalciferol,
      5000 IU) vs. placebo for 6 mo on insulin sensitivity (M-value by the gold standard method,
      the euglycemic hyperinsulinemic clamp). Secondary aims are to evaluate the effects of vitamin
      D3 vs. placebo on other indices of glucose metabolism (fasting glucose, 2-h plasma glucose
      post OGTT, HbA1c, insulin sensitivity index (HOMA-IS using fasting glucose and insulin),
      insulin secretion index (HOMA-B using fasting glucose and C-peptide), insulinogenic index
      [(C-peptide at 30 min post OGTT - C-peptide at 0 min)/(glucose at 30 min post OGTT - glucose
      at 0 min)] and disposition index (insulinogenic index x M-value)), the lipid profile, blood
      pressure and anthropometric measurements (weight, waist and hip circumference, bioimpedance
      analysis). Questionnaires on physical activity and sunlight exposure, and a food frequency
      questionnaire will be administered at 0 and 6 mo to adjust for confounding factors. At 0 and
      6 mo, biochemical markers associated with insulin sensitivity will be measured (point 2).

      Part 2: Mechanistic studies comparing, before and after vitamin D3 supplementation, changes
      in serum 25(OH)D with changes in blood markers associated with insulin sensitivity [hs-CRP,
      inflammatory cytokines (IL-6 and TNF-alpha), adiponectin, leptin, total and undercarboxylated
      osteocalcin].
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Actual">June 2, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in peripheral insulin sensitivity assessed by the euglycemic-hyperinsulinemic clamp at 6 months between placebo and vitamin D groups</measure>
    <time_frame>0 and 6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in glucose homeostasis (fasting glucose, 2h glucose post OGTT, HbA1c, HOMA-IS, HOMA-B, insulinogenic index, disposition index) at 6 months between placebo and vitamin D groups</measure>
    <time_frame>0 and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in blood pressure</measure>
    <time_frame>0 and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in lipid profile</measure>
    <time_frame>0 and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in anthropometry (weight, waist circumference and fat mass by bioimpedance analysis)</measure>
    <time_frame>0 and 6 months</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Changes from baseline in cytokines/adipokines at 6 months between placebo and vitamin D groups</measure>
    <time_frame>0 and 6 months</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">130</enrollment>
  <condition>Vitamin D-deficient</condition>
  <condition>Insulin-resistant</condition>
  <arm_group>
    <arm_group_label>Vitamin D supplementation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5000 IU of vitamin D3 for 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo pill for 6 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin D</intervention_name>
    <arm_group_label>Vitamin D supplementation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Caucasian men and women

          -  ≥25 yrs

          -  vitamin D deficiency [serum 25(OH)D concentration ≤55 nM]

          -  Abdominal obesity (waist circumference &gt;=102 cm for men and &gt;=88 cm for women) AND at
             least one factor associated with insulin resistance: (1) fasting serum triglycerides
             &gt;=1.7 mmol/L or treated dyslipidemia; (2) prediabetes or untreated type 2 diabetes
             (HbA1c &gt;=5.6% or fasting glucose &gt;=5.6 mmol/L or 2h glucose post OGTT &gt;=7.8 mmol/L);
             (3) first degree relative with type 2 diabetes; (4) history of gestational diabetes.

        Exclusion Criteria:

          -  Type 2 diabetes under drug therapy

          -  HbA1c &gt;7%

          -  BMI &gt;40 kg/m2

          -  pregnancy or breast-feeding;

          -  medication influencing vitamin D or glucose metabolism in the last 3 mo

          -  regular consumption of supplements containing &gt;400 IU/d of vitamin D3 over the last 2
             mo;

          -  renal insufficiency (creatinine clearance &lt;60 ml/min);

          -  cirrhosis,

          -  intestinal malabsorption (bypass surgery, celiac disease, etc);

          -  osteoporosis;

          -  history of nephrolithiasis;

          -  hypercalcemia (&gt;2.6 mM);

          -  hypercalciuria (&gt;0.6 fasting urine Ca/creatinine ratio);

          -  &gt;5% change in weight in the last 3 mo;

          -  diseases affecting glucose metabolism (e.g. hyperthyroidism);

          -  pacemaker (for bioimpedance only);

          -  inability to provide informed consent and complete questionnaires due to physical or
             mental problems.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Claudia Gagnon, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU de Québec Research Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU de Québec, Laval University Research Center</name>
      <address>
        <city>Quebec city</city>
        <state>Quebec</state>
        <zip>G1V 4G2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 24, 2013</study_first_submitted>
  <study_first_submitted_qc>January 29, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 30, 2013</study_first_posted>
  <last_update_submitted>January 25, 2018</last_update_submitted>
  <last_update_submitted_qc>January 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>CHU de Quebec-Universite Laval</investigator_affiliation>
    <investigator_full_name>Claudia Gagnon</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Vitamin D supplementation</keyword>
  <keyword>Insulin resistance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

